Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

Palleon Pharmaceuticals Raises 0 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

September 30, 2020 Dovie Salais

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today...

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

GlycanMediated

Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

The teen mental health crisis: a reckoning for Big Tech

Mental health support for fishers funded as seafood industry’s crisis revealed

Other people’s body odor could reduce social anxiety: study

Listening is first step to address Black boys’ mental health issues

‘Working till we drop’: why women are on the front line of French pension protests | France

Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases

You may have missed

The teen mental health crisis: a reckoning for Big Tech

Mental health support for fishers funded as seafood industry’s crisis revealed

Other people’s body odor could reduce social anxiety: study

Listening is first step to address Black boys’ mental health issues

‘Working till we drop’: why women are on the front line of French pension protests | France